



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/57 II (A61K 31/57, 31:565)		A1	(11) International Publication Number: WO 98/06404 (43) International Publication Date: 19 February 1998 (19.02.98)
(21) International Application Number: PCT/GB97/02133			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 8 August 1997 (08.08.97)			
(30) Priority Data: 9616700.2 9 August 1996 (09.08.96) GB			
(71) Applicant (for all designated States except US): THE REPRODUCTIVE MEDICINE TRUST [GB/GB]; 26 Elms Crescent, London SW4 8RA (GB).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): CAREY, Adam, Henry [GB/GB]; 101 Honeybrook Road, London SW12 0DL (GB). CAREY, Beverly, Jane [GB/GB]; 101 Honeybrook Road, London SW12 0DL (GB).			
(74) Agent: HALLYBONE, Huw, George; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).			
(54) Title: COMBINATIONS FOR HORMONE REPLACEMENT THERAPY CONTAINING A NATURAL OESTROGEN, A NATURAL PROGESTOGEN AND A NATURAL ANDROGEN			
(57) Abstract			
<p>The invention provides the use of a natural oestrogen, a natural progestogen and a natural androgen as a combined preparation for simultaneous, separate or sequential use in the treatment of menopausal or post-menopausal disorders in women. Preferably, the use is simultaneous administration of a mixture of oestradiol, progesterone and testosterone.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Switzerland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IS	Iceland	MW	Malawi	UG	Uganda
BY	Belarus	IT	Italy	MX	Mexico	UZ	Uzbekistan
CA	Canada	JP	Japan	NE	Niger	VN	Viet Nam
CF	Central African Republic	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CG	Congo	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CH	Switzerland	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CI	Côte d'Ivoire	KR	Republic of Korea	PL	Poland		
CM	Cameroun	KZ	Kazakhstan	PT	Portugal		
CN	China	LC	Saint Lucia	RU	Russian Federation		
CU	Cuba	LJ	Liechtenstein	SD	Sudan		
CZ	Czech Republic	LK	Sri Lanka	SE	Sweden		
DE	Germany	LR	Liberia	SG	Singapore		
DK	Denmark						
EE	Estonia						

COMBINATIONS FOR HORMONE REPLACEMENT THERAPY CONTAINING A NATURAL
OESTROGEN, A NATURAL PROGESTOGEN AND A NATURAL ANDROGEN

5 The present invention relates to the use of a combination of
hormones in the treatment of menopausal or post-menopausal
disorders in women.

The value of natural oestrogens as hormone replacement
10 therapy for post-menopausal women is well established.
After the menopause the ovarian production of oestradiol
falls markedly. Replacement of oestrogens has been shown to
alleviate menopausal symptoms such as hot flushes and
vaginal dryness, depression, and skin changes. It is also
15 known to protect against osteoporosis and cardiovascular
disease. Preliminary research also suggests protection
against pre-senile dementia.

Oestrogen replacement therapy, although beneficial in many
20 ways, has one serious side effect with important
implications: oestrogen tends to cause stimulation of the
endometrium. Before the menopause, this tendency is opposed
by another hormone of the ovarian endocrine cycle, namely
progesterone. The interaction between the effects of these
25 two hormones leads to the endometrium being repeatedly
stimulated and then shed in a monthly cycle with no net
thickening. If prolonged oestrogen replacement therapy is
taken in the absence of progesterone or a substance with
progesterone-like activity, known as a progestogen, the
30 oestrogen will cause unopposed stimulation of the
endometrium which may eventually develop into cancer.

For this reason oestrogen replacement therapy for women with
a uterus is usually offered as oestrogen together with a
35 synthetic progestogen. Progestogens may be natural or
synthetic. The natural progestogens include progesterone
and pregnenolone which are not orally active, and therefore
are not offered in conventional medical practice as

progestogenic oppositions for oestrogen replacement therapy. There are only two products listed in the British National Formulary under "progesterone". These are a pessary for administration *per vaginum* or *per rectum* (Cyclogest®, 5 Hoechst) and an intramuscular injection (Gestone®, Ferring). The two products are indicated for prevention of recurrent miscarriage, progesterone being a pro-gestational hormone.

Pharmaceutical interest and data production is, and has 10 been, sharply focused towards the development of synthetic orally active progestogens for use in the combined contraceptive pill. These include the progesterone analogues dehydrogesterone, hydroxyprogesterone and medroxyprogesterone, and the testosterone analogues 15 norethisterone and norgestrel and their derivatives.

Synthetic progestogens are described as anecdotally as "a necessary evil". They are taken to prevent endometrial cancer, but the concern is that they may act to antagonise 20 the beneficial effects of oestrogen replacement therapy, for example by altering serum lipids to increase the risk of cardiovascular disease. Furthermore, they often produce unacceptable side effects such as abdominal bloating, breast tenderness, headaches, hair loss, emotional lability or 25 breakthrough bleeding. Different progestogens have different side effect profiles, but it is not uncommon that an individual woman cannot find an acceptable progestogen and chooses to undergo major surgery in the form of a hysterectomy so that she can continue to take oestrogen. 30 replacement therapy without the need for progestogenic opposition. Others may choose not to take their prescribed progestogen whilst continuing with oestrogen replacement therapy and thereby risking the development of endometrial cancer. It has been found in practice that more than 20% of 35 women will stop hormone replacement therapy, despite its benefits, within nine months of commencing treatment, major reasons for this being the progestogenic side effects and dislike of continuing to menstruate.

Oestrogens and progestogens may be taken as tablets. For women with a uterus, the oestrogen tablet is taken every day with the addition of a tablet of progestogen for seven to 5 ten days each month to provoke a menstrual bleed. For older postmenopausal women there also exist some tablets containing both oestrogen and progestogen in combination which are taken daily in the hope of avoiding the monthly bleed. Many women have major problems with break-through 10 bleeding together with other progestogenic side effects.

Patches usually contain oestrogen alone but may also contain progestogen. They are applied to the buttock or arm and changed once or twice a week. The advantage over tablets is 15 that the hormone is absorbed transdermally, therefore avoiding the so-called "first pass effect" of hormones passing through the liver on the way from the gut to the systemic circulation and thereby activating liver enzymes and altering blood lipids. The disadvantage of patches is 20 that they are unsightly, often cause a local irritation at the site of application and tend to fall off in hot weather.

Implants are tiny pellets of oestradiol or testosterone which are inserted by a doctor, every six months, under the 25 skin of the anterior abdominal wall or the buttock. Their advantage is the improved compliance; their disadvantage that if the treatment is unacceptable it can be very difficult to remove the implant. Further some women develop reduced sensitivity to the extremely high serum levels of 30 oestradiol achieved. This results in the onset of menopausal symptoms as serum levels fall despite serum levels of oestradiol which are within the therapeutic range.

Gels and creams are becoming more popular. Oestradiol is 35 produced in gel form (Oestrogel®, Hoechst; Sandrena®, Orgaron). A metered dose is applied daily to the upper arms or thighs and rubbed in. It presents all the advantages of avoiding the first pass effect whilst not needing to wear an

unsightly patch or undergo a minor surgical procedure every six months. There is also a cream available in the UK which contains natural progesterone (Pro-Gest®, Transitions/Higer Nature) although it is not widely prescribed.

5

Unlike the synthetic progestogens, progesterone is not currently indicated for use in combination with oestrogen for hormone replacement therapy. Magos A.L. and Studd J.W.W. in Progress in Obstetrics and Gynaecology, Vol. 8, 10 pages 313-334 (J.W.W. Studd Ed.) found that a combination of progesterone with oestradiol resulted in irregular breakthrough bleeding. J.C. Montgomery and D. Crook in HRT and Osteoporosis, J. Drife and J.W.W. Studd Eds. Springer-Verlag, London, 1990, report that progesterone in doses high 15 enough to prevent endometrial hyperplasia is associated with unacceptable drowsiness due to the action of progesterone as a central nervous system depressant. In discussions of endometrial opposition, natural progesterone is often confused with the synthetic progestogens. Important 20 differences in their chemical structure which could lead to different actions and side effect profiles have not been considered.

Dr. J.R. Lee is a physician in the United States who has 25 lectured widely and written two books (Natural Progesterone, the Multiple Roles of a Remarkable Hormone and What your Doctor may not tell you about Menopause - the Breakthrough Book on Natural Progesterone). These books allege a wide variety of beneficial effects of natural progesterone, but 30 also contest the beneficial effects of oestrogen. They discount the evidence which supports the use of oestrogen, and they do not propose a combination therapy. Indeed, they suggest that oestrogen is used to excess and is thus responsible for most gynaecological complaints.

35

The androgens, which include testosterone, androstenedione and dehydroepiandrosterone, are considered to be male hormones, although they are also produced by the ovaries.

Testosterone is not commonly offered in preparation of hormone replacement therapy for women. There is a concern that supplementation of women with this male hormone may have an adverse effect on their risk of cardiovascular disease. Testosterone is also not indicated for women because of the possibility of masculinising side effects, such as facial hair and acne. However, J.W.W. Studd, W.P. Collins and J.R. Newton in Journal of Obstetrics and Gynaecology, Vol.84, pages 314-315 (1977), have suggested that testosterone may have a valuable role for some women in improving libido after the menopause.

It is an object of the present invention to provide an improved hormone replacement therapy for the treatment of menopausal and post-menopausal disorders in women.

It has been found, surprisingly, that a hormone replacement therapy comprising a combination of natural oestrogens, progestogens and androgens provides beneficial synergistic effects.

Accordingly, the present invention provides the use of a natural oestrogen, a natural progestogen and a natural androgen as a combined preparation for simultaneous, separate or sequential use in the treatment of menopausal or post-menopausal disorders in women.

Preferably, the natural oestrogen is selected from the group consisting of oestradiol, oestrone, oestriol and mixtures thereof. Preferably, the natural progestogen is selected from the group consisting of progesterone, pregnenolone and mixtures thereof. Preferably, the natural androgen is selected from the group consisting of testosterone, androstenedione, dehydroepiandrosterone (DHEA) and mixtures thereof. More preferably, the natural oestrogen consists essentially of oestradiol, the natural progestogen consists essentially of progesterone, and the natural androgen consists essentially of testosterone.

The combined preparation used in the present invention preferably has the natural oestrogen, natural progestogen and natural androgen in admixture with a suitable 5 pharmaceutical excipient for simultaneous administration of all three hormones. The combined preparation can be adapted for oral, transdermal (patch, cream or gel), subcutaneous implant, vaginal, rectal or parenteral administration. preferred formats are those already used for HRT and oral 10 contraceptive hormone administration. The combined preparation may, of course, comprise different hormones in different formats for separate or sequential use. For example, the combined preparation could comprise the oestrogen and androgen in oral administration format, and the 15 progestogen in a transdermal administration format. The hormones may, of course, be in the form of biologically acceptable prodrugs such as esters for sustained release in vivo.

20 The hormone concentrations and excipients used in the various combined preparation formats will be similar to those used for the administration of contraceptive hormones to pre-menopausal women, and/or the existing HRT therapies described above. The dosage levels will depend on the 25 bioavailability of the hormones in each given format. For example, there is a well known "first pass" effect with oral administration of these hormones, whereby a substantial fraction of the hormone is initially removed by the liver. Therefore, it is only really practicable to define the 30 present invention in terms of the salivary and serum levels of the hormones that are to be achieved for the duration of the therapy.

35 Preferably, the use according to the present invention achieves a salivary oestradiol level of 0.5 - 500 pg/ml, more preferably 5 - 300 pg/ml, and most preferably 50 - 300 pg/ml, or a serum oestradiol level of 100 - 1650 pmol/liter, more preferably 250 - 1,650 pmol/liter.

Preferably, the use according to the present invention achieves a serum oestrone level of from 5 - 50 $\mu\text{mol/liter}$, more preferably 10 - 50 $\mu\text{mol/liter}$, or a salivary oestrone level of 30 to 90 pmol/liter.

Preferably, the use according to the present invention achieves a serum oestriol level of from 1 - 1,000 $\mu\text{mol/liter}$, preferably 10 - 1,000 $\mu\text{mol/liter}$ and most preferably 100 - 800 $\mu\text{mol/liter}$, or a salivary oestriol level of from 1 to 10 nmol/liter.

Preferably, the use according to the present invention achieves a serum testosterone level of from 0.1 to 30 nmol/liter or a salivary testosterone level of from 18 - 140 pg/ml, more preferably 30 - 140 pg/ml, and most preferably 50 - 80 pg/ml.

Preferably, the use according to the present invention achieves a salivary dehydroepiandrosterone (DHEA) level of from 40 - 300 pg/ml, more preferably 100 - 300 pg/ml. The serum DHEA sulfate level is preferably 1 - 120 $\mu\text{mol/liter}$, more preferably 5 - 100 $\mu\text{mol/liter}$.

25 Preferably, the use according to the present invention achieves a serum level of androstenedione in the range of 4 - 100 nmol/liter, preferably 5 - 50 nmol/liter.

30 The salivary hormone levels defined above are determined using kits from Aeron Life Cycles Laboratories, California. The kits are FDA approved radioimmunoassay kits.

35 Further radioimmunoassay procedures for determination of these hormones in saliva are described in the following references, the entire contents of which are hereby incorporated by reference:-

of unconjugated estriol in saliva. *Clin. Chem.* 27:1080; (1981);

5 Walker R.F., Wilson D.W., Read G.F., Riad-Fahmy D 1980
Assessment of testicular function by the radioimmunoassay of
testosterone in saliva. *Int. J. Androl* 3:105; (1980)

10 Walker R.F., Read G.F., Riad-Fahmy D. Radioimmunoassay of
progesterone in saliva application to the assessment of
ovarian function. *Clin. Chem.* 25:2030; (1979);

Luisi M. Silvestri D, Maltini G, Castarsi A.L., Franchi F
1980 Radioimmunoassay of oestrone in male saliva. *Lancet*
2:542; (1980); and

15 Chearskul S., Rincon-Rodriguez I., Sofi S.B., Donaldson A.
Jeffcote L.S.L., Simple, direct assays for the measurement
of estradiol and progesterone in saliva, In:
Radioimmunoassay and Related Procedures in Medicine, IAEA,
20 Vienna 1982.

Similar radioimmunoassay or enzyme-linked immunosorbent
assay (ELISA) methods may be applied, with minor
modification, to the determinations of these hormones in
25 serum. Suitable antibodies for use in the assays are
available commercially, for example from Diagnostic Products
Corp. (U.K.) and Scherion Diagnostics (U.K.).

The menopausal or post-menopausal disorders that can be
30 treated in accordance with the present invention include:
osteopenia and osteoporosis; hypercholesterolaemia,
hypertension and atherosclerotic arterial disease; vasomotor
instability including hot flushes and night sweats;
urogenital atrophy including detrusor instability and stress
35 incontinence; poor libido; skin, hair and nail problems;
anxiety, depression and insomnia; memory loss and pre-senile
dementia, and mixtures thereof.

It is also envisaged that the combined preparations used in the present invention can also be used for the treatment of certain other hormone related deficiency conditions, including women with premature ovarian failure, Turner's 5 syndrome, testicular feminisation syndrome, sex change, hermaphroditism and pseudohermaphroditism, premenstrual syndrome, addback HRT for use with gonadotropin-releasing hormone analogues for endometriosis, pelvic pain, pelvic venous congestion, and benign breast disease.

10 Accordingly, in another aspect, this invention provides a method for the treatment of any of the disorders enumerated above, comprising administering to a human patient a therapeutically effective amount of a natural oestrogen, a 15 natural progesterogen and a natural androgen as a combined preparation.

An embodiment of the present invention will now be described further, by way of example, as follows.

20 **Example 1**
A clinical study of the effect of administration of a combined preparation in accordance with the present invention was performed as follows.

25 25 post-menopausal women with intact uteri were recruited. All complained of significant menopausal symptoms including a minimum of moderately severe hot flushes and night sweats, vaginal dryness and poor libido.

30 They were offered the following treatments: oestradiol, progesterone and testosterone (to three subjects); oestradiol and progesterone only (four subjects); progesterone alone (seven subjects); oestradiol, 35 testosterone and synthetic progestogen (seven subjects); and Org OD 14 (supplied by Organon Corporation under the Registered Trade Mark LIVIAL), a synthetic steroid with weak oestrogenic, progestrogenic and central effect (four

subjects).

The oestradiol, progesterone and testosterone were administered in conventional formats, the quantities of each 5 being titrated to achieve the following serum levels: Oestradiol 300-1000 pmol/liter; progesterone 5-50 nmol/liter; and testosterone 2-4 nmol/liter.

The testosterone serum levels were determined by competitive 10 radioimmunoassay on an ATS 180 automated machine using labelled antibody supplied by Scherion Diagnostics (UK). The oestradiol and progesterone serum levels were determined by automated ELISA on a Boehringer Mannheim ES700 machine using antibody supplied by Diagnostic Products Corp. (UK). The 15 measured between-batch coefficients of variation were: oestradiol 12.5% (at 200 pmol/liter); testosterone 10.8% (at 3.1 nmol/liter); and progesterone 9.2% (at 32 nmol/liter).

Synthetic progestogen was offered as either dydrogesterone 20 10mg or medroxyprogesterone acetate 5mg taken daily for the first ten days of each calendar month.

The subjects were reviewed after six months of treatment. Any reports of progestogenic side effects or complaints of 25 hot flushes and night sweats, vaginal dryness, poor libido, or unscheduled vaginal bleeding were noted. The results are shown in Table 1.

Table 1

30

	HRT	n	PSE	HF/S	VagD	Lib	VB	ASE(%)
	Org OD14	4	++++	+	-	++	+++	100
	En&Tn&Ps	7	+++	-	-	-	-	45
	Pn only	7	-	++	++	+	-	45
35	En&PN	4	-	-	-	+	-	25
	En&Pn&Tn	-	-	-	-	-	-	0

Key:

HRT type of hormone replacement therapy
n number of subjects
PSE progestogenic side effects
HF/S hot flushes and night sweats

5 VagD vaginal dryness
Lib loss of libido
VB unscheduled vaginal bleeding
ASE % of subjects experiencing any one or more side effect
after six months on the treatment

10 En natural oestrogen (oestradiol)
Pn Natural progestogen (progesterone)
Ps synthetic progestogen (hydrogesterone, norethisterone
or medroxyprogesterone acetate)
Tn natural androgen (testosterone)

15 From these it results it can be concluded that the
combination of a natural oestrogen, natural progestogen and
natural androgen affords the greatest relief from menopausal
symptoms with minimum adverse side effects.

20 The above embodiment has been described by way of example
only. Many other embodiments falling within the scope of
the accompanying claims will be apparent to the skilled
reader.

25

CLAIMS

1. Use of a natural oestrogen, a natural progestogen and a natural androgen as a combined preparation for simultaneous, separate or sequential use in the treatment of menopausal or post-menopausal disorders in women.
5
2. Use according to claim 1, wherein the natural oestrogen is selected from the group consisting of oestradiol, oestrone, oestriol and mixtures thereof.
10
3. Use according to claims 1 and 2, wherein the natural progestogen is selected from the group consisting of progesterone, pregnenolone and mixtures thereof.
15
4. Use according to claims 1, 2 and 3, wherein the natural androgen is selected from the group consisting of testosterone, androstenedione, dehydroepiandrosterone (DHEA) and mixtures thereof.
20
5. Use according to any preceding claim, wherein the natural oestrogen consists essentially of oestradiol, the natural progestogen consists essentially of progesterone, and the natural androgen consists essentially of testosterone.
25
6. Use according to any preceding claim, wherein said use achieves a salivary oestradiol level of 0.5 - 300 pg/ml or a serum oestradiol level of 100 μ mol/liter - 1,650 μ mol/liter.
30
7. Use according to any preceding claim, wherein said use achieves a salivary oestrone level of 30 to 90 pmol/liter or a serum oestrone level of 5 - 50 micromol/liter.
35
8. Use according to any preceding claim, wherein said use

achieves a salivary oestriol level of 1 to 10 nmol/liter or a serum oestriol level of 1 - 1,000 micromol/liter.

- 5 9. Use according to any preceding claim, wherein said use achieves a salivary testosterone level of from 18 pg/ml to 740 pg/ml or a serum testosterone level of from 0.1 to 30 nmol/liter.
- 10 10. Use according to any preceding claim, wherein said use achieves a salivary dehydroepiandrosterone (DHEA) level of from 40 pg/ml to 300 pg/ml or a serum DHEA sulfate level of 1 - 120 micromol/liter.
- 15 11. Use according to any preceding claim, wherein said use achieves a serum level of androstenedione of 4 - 100 nmol/liter.
12. Use according to any preceding claim, wherein said 20 combined preparation is a single medicament comprising said natural oestrogen, said natural progestogen and said natural androgen admixed with pharmaceutical excipients for simultaneous administration.
- 25 13. Use according to any preceding claim, wherein said combined preparation comprises a patch, cream or gel for transdermal administration.
14. Use according to any preceding claim, wherein said 30 combined preparation comprises a subcutaneous implant.
15. Use according to any preceding claim, wherein said combined preparation comprises a cream, gel or pessary for vaginal administration.
- 35 16. Use according to any preceding claim, wherein said menopausal or post-menopausal disorder is selected from the group consisting of osteopenia and osteoporosis;

5 hypercholesterolaemia, hypertension and atherosclerotic arterial disease; vasomotor instability including hot flushes and night sweats; urogenital atrophy including detrusor instability and stress incontinence; poor libido; skin, hair and nail problems; anxiety, depression and insomnia; memory loss and pre-senile dementia, and mixtures thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 97/02133A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/57 // (A61K31/57, 31:565)

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HARGROVE J.T. ET AL: "An alternative method of hormone replacement therapy using the natural sex steroids" INFERTILITY AND REPRODUCTIVE MEDICINE CLINICS OF NORTH AMERICA, 1995, 6/4 (653-674), USA, XP002045938 see page 668, paragraph 1 see table 3 ---	1-16
X	BOUDET J. ET AL: "Study of the epicutaneous kinetic diffusion of a cream containing estrone, estradiol, testosterone and pregnenolone (Fadiamone (R)) in menopausal women" NOUV. DERMATOL., 1994, 13/9 (658-661), FRANCE, XP002045939 see abstract ---	1-16 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubt on priority, claim(s) or rights, or which is cited to explain the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date of priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

1	Date of the actual completion of the international search: 6 November 1997	Date of mailing of the international search report 24/11/1997
	Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentien 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax. (+31-70) 340-3018	Authorized officer Leherte, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 97/02133

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ALDEN J.C.: "Osteoporosis - A review" CLIN. THER., 1989, 11/1 (3-14), USA, XP002045940 see page 10, column 2, paragraph 3 - page 11, column 2 -----	1-16
X	FERNANDEZ-GUASTI, ALONSO ET AL: "Synergistic action of estradiol, progesterone and testosterone on rat proceptive behavior" PHYSIOL. BEHAV., 1991, 50, 1007-11, XP002045941 see page 1010, column 2, line 2-5 -----	1-16